NASDAQ · MLECW
Moolec Science SA Warrant financials
$0.0134−11.26%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '25 Jun 30 | Q4 '24 Jun 30 | Q4 '23 Jun 30 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Gross margin | — | — | — |
| Operating income | — | — | — |
| Net income | — | — | — |
| Net margin | — | — | — |
| Diluted EPS | — | — | — |
| EBITDA | $0.00 | $0.00 | $0.00 |
| Operating cash flow | — | — | — |
| Free cash flow | — | — | — |
| Diluted shares | 0.4M | 0.4M | 0.3M |
Balance sheet
| Period end | Jun 30 | Jun 30 | Jun 30 |
|---|---|---|---|
| Cash & equivalents | $767.9K | $53.0M | $2.5M |
| Short-term investments | $0.00 | $0.00 | $306.0K |
| Total debt | $246.8M | $442.9M | $2.6M |
| Total assets | $204.7M | $949.8M | $24.1M |
| Total liabilities | $287.6M | $699.8M | $13.9M |
| Shareholders' equity | -$82.9M | $250.0M | $10.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology